Lineage Cell Therapeutics (LCTX) EBITDA Margin (2010 - 2026)

Lineage Cell Therapeutics' EBITDA Margin history runs 17 years deep, the most recent figure standing at 440.17% for Q1 2026.

• On a quarterly basis, EBITDA Margin fell 708.0% year-over-year to 440.17% in Q1 2026; TTM through Mar 2026 was 255.14%, a 3204.0% decrease from a year earlier, with the FY2025 full-year figure at 251.57%, down 2547.0% from the prior year.
• EBITDA Margin declined to 440.17% in Q1 2026 per LCTX's latest filing, from 99.09% in the prior quarter.
• Across five years, EBITDA Margin topped out at 92.99% in Q2 2022 and bottomed at 715.37% in Q2 2025.
• The 5-year median for EBITDA Margin is 278.37% (2023), against an average of 291.9%.
• Across the five-year window, EBITDA Margin soared 168094 bps in 2022 and sank 36297 bps in 2023, its largest moves.
• Year by year, EBITDA Margin stood at 346.68% in 2022, then increased by 12 bps to 304.69% in 2023, then soared by 42 bps to 178.17% in 2024, then jumped by 44 bps to 99.09% in 2025, then sank by 344 bps to 440.17% in 2026.
• Per Business Quant, the three latest LCTX EBITDA Margin figures stand at 440.17% (Q1 2026), 99.09% (Q4 2025), and 102.85% (Q3 2025).